Signature-reversion direction is internally contradictory. You state that a drug signature “similar or dissimilar” to a disease signature may “restore or reverse” the phenotype, respectively; this conflicts with your later LINCS statement that similarity = disease-inducing and dissimilarity = therapeutic. Which direction is intended?
Table 4: the header says colspan=”4″ but lists five categories (CGS, KD, drug perturbagen, overexpression, proteomic), while each row has only four numeric columns; the source URL https://linc.org is also incorrect for LINCS.
ATC factual error: you state the ATC classification has “14 levels”; WHO ATC has 5 levels.
Table 2 statin MOA is wrong: statins are HMG-CoA reductase inhibitors, not “β-Hydroxy β-methylglutaryl-CoA antagonists.”
Nomenclature errors: “DISC mutation” should be DISC1; Table 5 contains misspellings/incorrect drug names (“Nafitrofuryl,” “Papavarine,” “Dutoglipitin/Aloglipitin,” “Arcaire sulfate”). Please verify and correct.